ABCL
AbCellera Biologics Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
0.92
P/S
14.20
EV/EBITDA
-6.02
DCF Value
$-2.80
FCF Yield
-16.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
100.0%
Operating Margin
-289.0%
Net Margin
-194.9%
ROE
-14.2%
ROA
-11.5%
ROIC
-13.8%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $44.9M | $-8.9M | $-0.03 |
| FY 2025 | $75.1M | $-146.4M | $-0.49 |
| Q3 2025 | $9.0M | $-57.1M | $-0.19 |
| Q2 2025 | $17.1M | $-34.7M | $-0.12 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
CA
Exchange
NASDAQ
Beta
0.85
AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners. AbCellera Biologics Inc. has a research collaboration and license agreement with Eli Lilly and Company. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.